Vnitr Lek 2024, 70(6):390-397 | DOI: 10.36290/vnl.2024.077

Indications, specifics and reimbursement of glucose sensors in type 2 diabetes patients

Kateřina Štechová

Interní klinika UK 2. LF a FN v Motole, Praha

The use of glucose sensors first changed self-monitoring and also the treatment of patients with type 1 diabetes mellitus, as it enabled safer and more flexible reaching of physiological blood glucose values. Despite certain inconsistencies in subsequent studies, it is clear that this form of glycaemic self-monitoring has the potential to improve diabetes control in patients with type 2 diabetes as well (DM2; possibly also with other forms of diabetes). In addition, DM2 patients generally appreciate this type of glycaemic self-monitoring. The effect of using personal continuous monitoring of glucose concentration (either in real time or in the form of so-called intermittent scanning) in patients with DM2 requiring insulin therapy, especially in the form of an intensified insulin regimen, has been convincingly documented in randomized controlled trials. Moreover, in some studies, these patients were treated primarily by general practitioners. There are also positive reports on the benefit of continuous glucose monitoring in DM2 patients treated by other forms of therapy than with an intensified insulin regimen. Currently, in the Czech Republic, however, reimbursement of glucose sensors by the insurance company is restricted to a diagnosis of type 1 diabetes mellitus. Patients with DM2 can of course use them, but as self-payers.

Keywords: time in range, type 2 diabetes mellitus, glucose sensors, glycosylated hemoglobin, diabetes control, continuous glucose monitoring.

Accepted: September 19, 2024; Published: October 3, 2024  Show citation